New drug combo shows promise for tough lung cancer
NCT ID NCT07171606
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has not been treated before. About 240 adults will take part to see if the drug shrinks tumors and how safe it is. The goal is to find better ways to control the disease and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of The Shanghai Pulmonary Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a Triple-Drug combo outsmart Immunotherapy-Resistant lung cancer?
- Which palliative care approach boosts quality of life in advanced lung cancer?
- Experimental drug combo targets Hard-to-Treat lung cancer
- Can a smartphone app ease the burden of advanced lung cancer?
- Breath of discovery: simple test may sniff out lung cancer